<unk>  is an anaplastic lymphoma kinase (ALK) inhibitor primarily used for the treatment of ALK positive metastatic NSCLC. Previously, it was only indicated for patients who had developed resistant to crizotinib, another ALK inhibitor, but has since had its usage expanded to serve as a primary option for metastatic NSCLC.
Ceritinib
Axitinib
Abrocitinib
Sunitinib
Baricitinib
Erdafitinib
Upadacitinib
Dacomitinib